April 15, 2013
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that
David A. Dodd
has been appointed President and Chief Executive Officer of the Company, succeeding
, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.
"With the appointment of David, we are taking an important first step in transforming Aeterna Zentaris from a company focused on R&D to a company focused on commercializing the promising compounds in our pipeline," said
, Chairman of the, Board of Directors. "David's reputation in the industry as a 'transformation specialist' is well deserved, with a record of successful and dramatic transformations of multiple pharmaceutical and biotechnology enterprises. David is a strong, focused leader with the ability to motivate employees, and significantly enhance shareholder value. We are delighted that he is joining our management team, and we look forward to his leadership and stewardship of Aeterna Zentaris."
"I am honored and excited to have the opportunity to lead Aeterna Zentaris," said Mr. Dodd. "Building on the existing strong R&D foundation, my focus will be to serve the needs of patients, shareholders and employees through successful development and commercialization of novel, differentiated products that enhance and may save lives. I am fully committed to rewarding our shareholders with sustained growth and future profitability. Moreover, I look forward to the challenge of moving this company forward, and working with its highly dedicated staff."
Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From
, Mr. Dodd was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. From
, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the Company to Stem Cells, Inc., in
During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of that company increased from
to an all-cash sale to Millipore Corporation in
. That successful transformation followed his five-year term as President and CEO of Solvay Pharmaceuticals, Inc. and as Chairman of its subsidiary Unimed Pharmaceuticals, Inc. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories.
Currently, he serves as Chair, Board of Directors, of GeoVax, Inc., a biotechnology company developing innovative, patented HIV/AIDS vaccines; as a Director on the Board of Aruna Biomedical, a privately-held life science development company focused on the development and commercialization of stem cell research products and services; and, as a Director on the Board of PNP Therapeutics, a clinical stage company, developing a novel nucleoside-booster treatment for solid tumor mass cancers.